Lyka Labs Share Price

67.38-2.69 (-3.83%)

Closed
As On: 19 Jun, 2026, 03:42 PM IST
As On: 19 Jun, 2026, 03:40 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	70.06
High	71.03
Low	66.86
Prev Close	70.06
Volume	50,100
VWAP(₹)	68.16

Share Price	Value
Today/Current/Last	67.3868.05
Previous Day	70.0670.40

Lyka Labs Share Recommendations

Recent Recos

Target₹70
OrganizationNirmal Bang Securities
BUY

View all Stock Recommendations

News & Analysis

NCLAT allows Lyka Labs appeal; asks Modi Lifecare to pay Rs 63 lakh or face insolvency proceedings
News
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - GST
Announcements
Announcement under Regulation 30 (LODR)-Allotment
Announcements
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requiremen..
Announcements

View all Lyka Labs Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	31.89	37.75	33.66	34.25	34.62
Total Income Growth (%)	-15.53	12.18	-1.73	-1.08	-15.92
Total Expenses	31.23	41.35	31.45	30.76	30.44
Total Expenses Growth (%)	-24.46	31.48	2.24	1.07	-19.83
EBIT	0.66	-3.60	2.21	3.49	4.19
EBIT Growth (%)	-	-263.06	-36.73	-16.73	30.20
Profit after Tax (PAT)	-2,000.00	-3.36	0.93	1.77	2.71
PAT Growth (%)	-	-460.00	-47.36	-34.59	29.19
EBIT Margin (%)	2.06	-9.53	6.55	10.18	12.09
Net Profit Margin (%)	0.00	-8.89	2.77	5.17	7.82
Basic EPS (₹)	-0.04	-0.94	0.25	0.49	0.75

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	31.99	34.19	29.84	31.24	33.80
Total Income Growth (%)	-6.43	14.55	-4.46	-7.57	-18.14
Total Expenses	30.89	38.20	27.82	28.45	29.59
Total Expenses Growth (%)	-19.12	37.29	-2.19	-3.87	-21.09
EBIT	1.09	-4.01	2.02	2.79	4.21
EBIT Growth (%)	-	-298.38	-27.57	-33.62	11.10
Profit after Tax (PAT)	0.28	-3.63	0.81	1.31	2.70
PAT Growth (%)	-	-545.44	-37.67	-51.60	9.12
EBIT Margin (%)	3.42	-11.73	6.78	8.94	12.44
Net Profit Margin (%)	0.88	-10.61	2.73	4.18	7.98
Basic EPS (₹)	0.08	-1.02	0.22	0.36	0.75

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	140.73	112.65	96.47	196.18	87.81
Total Revenue Growth (%)	24.92	16.77	-50.82	123.41	35.98
Total Expenses	129.60	113.17	102.25	130.41	100.83
Total Expenses Growth (%)	14.52	10.68	-21.60	29.34	8.15
Profit after Tax (PAT)	8.01	-2.49	-13.21	39.00	-11.55
PAT Growth (%)	-	-	-133.88	-	-
Operating Profit Margin (%)	9.67	3.92	6.54	44.25	14.98
Net Profit Margin (%)	5.78	-2.23	-14.19	20.09	-13.39
Basic EPS (₹)	2.22	-0.79	-4.63	13.57	-4.07

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	137.04	108.04	84.04	167.07	64.47
Total Revenue Growth (%)	26.84	28.56	-49.69	159.13	48.76
Total Expenses	125.57	108.92	90.08	102.16	81.44
Total Expenses Growth (%)	15.28	20.92	-11.83	25.44	15.13
Profit after Tax (PAT)	8.23	-2.27	-13.29	39.90	-14.46
PAT Growth (%)	-	-	-133.30	-	-
Operating Profit Margin (%)	10.22	3.68	6.86	51.61	13.79
Net Profit Margin (%)	6.10	-2.13	-16.48	24.27	-23.22
Basic EPS (₹)	2.28	-0.72	-4.65	13.87	-5.08

All figures in Rs Cr, unless mentioned otherwise

Insights

Topline Contraction
Sales de-grew by 6.24%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 2.59% of its operating revenues towards interest expenses and 32.58% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	176.21	156.72	151.52	185.61	190.01
Total Assets Growth (%)	12.43	3.43	-18.37	-2.31	-5.07
Total Liabilities	71.54	87.38	104.77	171.35	214.40
Total Liabilities Growth (%)	-18.13	-16.60	-38.85	-20.08	-0.11
Total Equity	103.58	68.27	45.67	13.49	-25.09
Total Equity Growth (%)	51.73	49.47	238.53	-	-
Current Ratio (x)	1.45	1.35	1.36	0.53	0.59
Total Debt to Equity (x)	0.36	0.81	1.55	9.66	-6.24
Contingent Liabilities	33.56	36.22	36.81	46.56	31.82

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	205.58	185.88	178.86	208.51	213.37
Total Assets Growth (%)	10.60	3.92	-14.22	-2.28	-3.57
Total Liabilities	69.55	85.47	101.35	163.30	208.25
Total Liabilities Growth (%)	-18.63	-15.67	-37.94	-21.58	3.17
Total Equity	134.94	99.33	76.43	44.44	4.41
Total Equity Growth (%)	35.85	29.96	71.98	907.71	-76.52
Current Ratio (x)	1.48	1.39	1.41	0.51	0.58
Total Debt to Equity (x)	0.27	0.56	0.92	2.87	36.39
Contingent Liabilities	33.56	35.84	24.58	35.34	22.78

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	1.90	1.77	8.95	79.25	8.81
Net Cash used in Investing Activities	-11.80	-9.49	7.35	-6.17	-0.16
Net Cash flow from Financing Activities	5.29	1.95	-21.64	-63.18	-11.80
Net Cash Flow	-4.60	-5.76	-5.34	9.90	-3.15
Closing Cash & Cash Equivalent	1.34	5.95	11.71	17.05	7.15
Closing Cash & Cash Equivalent Growth (%)	-77.41	-49.20	-31.32	138.35	-30.56
Total Debt/ CFO (x)	19.40	31.29	7.89	1.63	18.27

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	3.27	3.09	6.87	76.53	5.75
Net Cash used in Investing Activities	-13.10	-8.61	6.77	-4.33	0.13
Net Cash flow from Financing Activities	5.26	2.71	-20.33	-63.35	-7.75
Net Cash Flow	-4.57	-2.81	-6.69	8.85	-1.88
Closing Cash & Cash Equivalent	1.32	5.89	8.70	15.38	6.53
Closing Cash & Cash Equivalent Growth (%)	-77.60	-32.31	-43.47	135.63	-22.32
Total Debt/ CFO (x)	11.26	17.96	10.18	1.67	27.90

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 9.41 cr for investing activities which is an YoY decrease of 20.19%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	7.73	-3.65	-29.07	292.38	0.00
Return on Capital Employed (%)	10.33	3.66	5.12	99.57	9.17
Return on Assets (%)	4.54	-1.58	-8.71	21.01	-6.08
Interest Coverage Ratio (x)	8.87	3.51	1.71	5.13	0.50
Asset Turnover Ratio (x)	0.83	0.72	0.55	0.82	45.39
Price to Earnings (x)	45.05	-142.86	-24.33	9.98	-6.46
Price to Book (x)	3.48	5.14	7.07	29.17	-2.89
EV/EBITDA (x)	19.68	23.37	18.85	4.86	10.82
EBITDA Margin (%)	14.56	15.44	21.74	53.19	24.63

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	6.09	-2.28	-17.38	89.79	-327.92
Return on Capital Employed (%)	8.56	2.61	3.71	73.87	5.09
Return on Assets (%)	4.00	-1.22	-7.42	19.13	-6.77
Interest Coverage Ratio (x)	8.78	3.38	1.65	5.03	0.65
Asset Turnover Ratio (x)	0.69	0.58	0.42	0.78	0.29
Price to Earnings (x)	43.86	-156.25	-24.21	9.76	-5.16
Price to Book (x)	2.67	3.53	4.20	8.75	16.93
EV/EBITDA (x)	19.62	24.76	20.14	5.01	13.78
EBITDA Margin (%)	15.02	15.23	23.64	60.97	26.71

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Lyka Labs	-23.97	2.65	-10.85	-7.00	-5.74	10.88	-6.57	-8.12	-2.81	1.17	0.52	9.22
Medico Remedies	26.97	4.68	17.37	26.22	8.54	13.57	9.62	6.35	1.58	1.66	0.25	3.21
Medicamen Bio	28.58	1.13	3.49	5.45	2.59	11.78	7.82	4.95	7.22	2.54	0.17	-1.44
Ambalal Sarabhai	13.75	1.55	11.24	12.59	6.33	5.90	11.36	8.59	2.32	1.27	0.33	3.85
Aarey Drugs	52.42	1.58	2.63	6.84	1.33	4.25	2.20	0.84	1.39	1.81	0.33	4.93
Add More

Annual Ratios (%)

Choose from Peers

Nectar Lifesc
Brooks Labs
Natural Capsule
Alpa Labs
Krebs Biochem

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Lyka Labs Stock Performance	-3.83	7.96	14.09	7.12	-42.82	-30.89	11.56
Medico Remedies Stock Performance	-1.03	-1.64	3.92	-7.16	-23.16	-48.58	0.00
Medicamen Bio Stock Performance	1.38	-15.78	-12.46	-27.59	-47.01	-64.97	0.00
Ambalal Sarabhai Stock Performance	-0.66	3.27	-0.03	0.00	0.00	0.00	0.00
Aarey Drugs Stock Performance	2.09	-8.43	-5.18	6.47	56.94	198.57	0.00
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	2,07,58,217	58.16 %	0.00
Pledge	0	0.00 %	0.00
FII	1,02,851	0.29 %	0.11
DII	2,37,051	0.66 %	0.00
MF	3,400	0.01 %	0.00
Others	1,45,91,881	40.89 %	-0.11

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	58.16	58.16	58.16	58.16
Pledge	0.00	0.00	0.00	0.00
FII	0.29	0.17	0.17	0.16
DII	0.66	0.66	0.66	0.66
Mutual Funds	0.01	0.01	0.01	0.01
Others	40.89	41.01	41.01	41.02

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
Board Meeting
Audited Results
May 12, 2026
Board Meeting
Others
Mar 23, 2026
Board Meeting
Quarterly Results
Jan 14, 2026

Board Meetings

Announced on	Meeting on
May 12, 2026	May 25, 2026
Audited Results
Mar 23, 2026	Mar 31, 2026
Others
Jan 14, 2026	Jan 29, 2026
Quarterly Results
Oct 23, 2025	Nov 12, 2025
Quarterly Results & Others
Sep 24, 2025	Sep 29, 2025
Others

Dividends
No Data Available
Bonus
No Data Available
Splits
No Data Available
Rights
Announced on Ex-Date
Sep 30, 1993 Oct 22, 1993
Rights ratio: 1 share for every 2 held at a price of Rs 30.0
AGM/EGM Meetings
Announced on Meeting on
Jul 08, 2025 Aug 01, 2025
-
Jan 31, 2025 Mar 04, 2025
-
Jul 15, 2024 Aug 09, 2024
Book closure from Aug 2, 2024 to Aug 9, 2024
Jan 23, 2024 Feb 24, 2024
-
Jan 19, 2024 Feb 20, 2024
-

Announced on	Ex-Date
Sep 30, 1993	Oct 22, 1993
Rights ratio: 1 share for every 2 held at a price of Rs 30.0

Announced on	Meeting on
Jul 08, 2025	Aug 01, 2025
-
Jan 31, 2025	Mar 04, 2025
-
Jul 15, 2024	Aug 09, 2024
Book closure from Aug 2, 2024 to Aug 9, 2024
Jan 23, 2024	Feb 24, 2024
-
Jan 19, 2024	Feb 20, 2024
-

About Lyka Labs

Lyka Labs Ltd., incorporated in the year 1976, is a Small Cap company (having a market cap of Rs 240.48 Crore) operating in Pharmaceuticals sector.

Lyka Labs Ltd. key Products/Revenue Segments include Formulations, Processing Charges, Royalty Income, Export Incentives, Other Operating Revenue, Commission for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 28.64 Crore, down 10.19 % from last quarter Total Income of Rs 31.89 Crore and down 16.37 % from last year same quarter Total Income of Rs 34.25 Crore. Company has reported net profit after tax of Rs -8.07 Crore in latest quarter.

The company’s top management includes Mr.Babulal Jain, Mr.Kunal Gandhi, Mr.Yogesh B Shah, Mr.Prashant Godha, Mr.Shashil Mendosa, Ms.Archana S Yadav, Mrs.Dhara Shah, Mr.Neeraj Golas, Mr.Shekhar R Singh. Company has D Kothary & Co. as its auditors. As on 31-03-2026, the company has a total of 3.57 Crore shares outstanding.

Lyka Labs Share Price Today is Rs. 67.38. On previous day, the Lyka Labs Share Price (NSE) closed at Rs. 70.51, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 58.16% of the stake in Lyka Labs shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Lyka Labs stocks was 0.29% as compared to 0.17% in Dec 2025 with increase of 0.12%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.66% as compared to 0.66% in Dec 2025 with decrease of 0.0%. Out of the total DII holdings in Lyka Labs shares 0.01% was held by mutual funds. The rest including public held is 40.89%. Lyka Labs stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Lyka Labs Dividend: Ever since 1976, Lyka Labs dividends has been paid out around 0 times. As on 19 Jun, 2026, 03:42 PM IST, The overall dividend yield for Lyka Labs stands at 0.0%. The last dividend paid was on null (Rs. null). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. -2.81.

Lyka Labs Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 28.64 Cr. of sales and 10.19% of quarterly net loss, there have been multiple ups and downs in the Lyka Labs stock prices in the past few weeks. For example, Lyka Labs stock price on 11th of June 2026 was around Rs. 69.0. Lyka Labs share price now stands at an average of Rs. 67.38. Judging by last week's performance, stock is in up trend.

Lyka Labs has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Lyka Labs share.

Historical Prices and Performance:
Lyka Labs, incorporated in 1976 is a Small Cap company (with a market cap of Rs. 250.04) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Lyka Labs stock was -10.85%, 7.73%, -3.65%, -29.07% and 292.38% respectively.
The Lyka Labs share gave a 3 year return of -40.55% as compared to Nifty 50 which gave a return of 28.38%.
Lyka Labs announced 0.0% final dividend on null.

Key Metrics:
PE Ratio of Lyka Labs is -25.09
Prices/Sales Ratio of Lyka Labs is 1.24
Price/Book Ratio of Lyka Labs is 2.77

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Lyka Labs, major competitors and peers include Medico Remedies, Medicamen Bio, Ambalal Sarabhai and Aarey Drugs. As of Dec 2025, the dividend yield of Lyka Labs stands at 0.0% while Medico Remedies, Medicamen Bio, Ambalal Sarabhai and Aarey Drugs stand at 0.0%, 0.0%, 0.0% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at -25.09 and 2.77 respectively.

Leadership of Lyka Labs :
Shekhar R Singh is Co. Secretary & Compl. Officer
Babulal Jain is Chairman
Kunal Gandhi is Managing Director & CEO
Yogesh B Shah is WholeTime Director & CFO
Shashil Mendosa is Non Executive Director
Prashant Godha is Non Executive Director
Dhara Shah is Independent Director
Neeraj Golas is Independent Director
Archana S Yadav is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

4801/B & 4802/A,G.I.D.C. Industrial Estate,Ankleshwar, Gujarat - 393002

Contact

companysecretary@lykalabs.com.

http://www.lykalabs.com

PE Ratio(x)	-23.97
EPS - TTM(₹)	-2.81
MCap(₹ Cr.)	240.48
MCap Rank	104
PB Ratio(x)	2.75
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	121.44
52W Low(₹)	44.10
MCap/Sales	1.24
Beta(1 Month)	1.16
BV/Share(₹)	25.45

PE Ratio(x)	-24.21
EPS - TTM(₹)	-2.81
MCap(₹ Cr.)	242.87
MCap Rank	117
PB Ratio(x)	2.75
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	121.00
52W Low(₹)	44.49
MCap/Sales	1.24
Beta(1 Month)	0.69
BV/Share(₹)	25.45

1 Day	-3.83%
1 Month	12.79%
3 Months	28.05%
1 Year	-39.96%
3 Years	-45.57%
5 Years	27.49%

1 Day	-3.33%
1 Month	15.05%
3 Months	29.62%
1 Year	-39.3%
3 Years	-44.93%
5 Years	27.79%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Lyka Labs Share Price

Key Metrics